Low-intensity pulsed ultrasound: Nonunions

Dijkman, Bernadette G; Sprague, Sheila; Bhandari, Mohit

doi:10.4103/0019-5413.50848

Cited by 26 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,20,21 Among all these methods, LLLT outshines other modalities due to the advantage of being non-invasive and the ease of application in clinical use. However, there is still no standard protocol for LLLT application to promote bone healing in the literature.…”

Section: 18mentioning

confidence: 99%

The efficacy of low-level 940 nm laser therapy with different energy intensities on bone healing

et al. 2017

View full text Add to dashboard Cite

The aim of this study was to evaluate the efficacy of low-level 940 nm laser therapy with energy intensities of 5, 10 and 20 J/cm 2 on bone healing in an animal model. A total of 48 female adult Wistar rats underwent surgery to create bone defects in the right tibias. Low-level laser therapy (LLLT) was applied immediately after surgery and on post-operative days 2, 4, 6, 8, 10 and 12 in three study groups with energy intensities of 5 J/cm 2 , 10 J/cm 2 and 20 J/cm 2 using a 940 nm Gallium-Aluminium-Arsenide (Ga-Al-As) laser, while one control group underwent only the tibia defect surgery. All animals were sacrificed 4 or 8 weeks post-surgery. Fibroblasts, osteoblasts, osteocytes, osteoclasts and newly formed vessels were evaluated by a histological examination. No significant change was observed in the number of osteocytes, osteoblasts, osteoclasts and newly formed vessels at either time period across all laser groups. Although LLLT with the 10 J/cm 2 energy density increased fibroblast activity at the 4th week in comparison with the 5 and 20 J/cm 2 groups, no significant change was observed between the laser groups and the control group. These results indicate that low-level 940 nm laser with different energy intensities may not have marked effects on the bone healing process in both phases of bone formation.

show abstract

Section: 18mentioning

confidence: 99%

The efficacy of low-level 940 nm laser therapy with different energy intensities on bone healing

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Among the various LIPUS parameters reported in experimental results, the most widely used is a 1.5 MHz ultrasound fundamental frequency, with a pulse width of 200 µs, repeated at 1 kHz (equivalent to 20% duty cycle), at a spatial average temporal average (SATA) intensity of 30 mW/cm 2 . These LIPUS parameters have been applied to fresh fracture healing [12,13], delayed union [14], and nonunion [15], and they have been found to be effective in accelerating fracture healing, which has been approved by U.S. Food and Drug Administration (FDA), as well as supported by The National Institute for Health and Care Excellence (NICE) in the UK. The same set of LIPUS parameters has also been used for intra-oral dental tissue formation and stem cell growth and differentiation [16,17].…”

Section: Introductionmentioning

confidence: 99%

A Low-Intensity Pulsed Ultrasound Interface ASIC for Wearable Medical Therapeutic Device Applications

Ye,

Jiang,

Wang

et al. 2024

Electronics

View full text Add to dashboard Cite

Low-intensity pulsed ultrasound (LIPUS) is a non-invasive medical therapy that has attracted recent research interest due to its therapeutic effects. However, most LIPUS driver systems currently available are large and expensive. We have proposed a LIPUS interface application-specific integrated circuit (ASIC) for use in wearable medical devices to address some of the challenges related to the size and cost of the current technologies. The proposed ASIC is a highly integrated system, incorporating a DCDC module based on a charge pump architecture, a high voltage level shifter, a half-bridge driver, a voltage-controlled oscillator, and a corresponding digital circuit module. Consequently, the functional realization of this ASIC as a LIPUS driver system requires only a few passive components. Experimental tests indicated that the chip is capable of an output of 184.2 mW or 107.2 mW with a power supply of 5 V or 3.7 V, respectively, and its power conversion efficiency is approximately 30%. This power output capacity allows the LIPUS driver system to deliver a spatial average temporal average (SATA) of 29.5 mW/cm2 or 51.6 mW/cm2 with a power supply of 3.7 V or 5 V, respectively. The total die area, including pads, is 4 mm2. The ASIC does not require inductors, improving its magnetic resonance imaging (MRI) compatibility. In summary, the proposed LIPUS interface chip presents a promising solution for the development of MRI-compatible and cost-effective wearable medical therapy devices.

show abstract

“…Studies 63 have shown that ultrasound increases cellular migration, 64 proliferation, and localized vascularization, reducing 65 inflammation and accelerating soft tissue healing [23, 66 24,26,27,28,29,30]. The Food and Drug Administra-67 tion (FDA) has approved ultrasound treatment systems 68 for non-union fracture healing, musculoskeletal pain, 69 and soft tissue injuries as a standalone or combination 70 therapy [31,32,33,34,35].…”

mentioning

confidence: 99%

Sustained acoustic medicine treatment of discogenic chronic low back pain: A randomized, multisite, double-blind, placebo-controlled trial

Ortiz,

Motyka,

Petterson

et al. 2024

BMR

View full text Add to dashboard Cite

BACKGROUND: Sustained acoustic medicine (SAM) is a noninvasive long-term treatment that provides essential mechanical and thermal stimulus to accelerate soft tissue healing, alleviate pain, and improve physical activity. SAM increases localized deep tissue temperature, blood flow, cellular proliferation, migration, and nutrition exchange, resulting in reduced inflammation and an increased rate of tissue regeneration. OBJECTIVE: To assess the efficacy of SAM treatment of discogenic back pain in the lower spinal column to reduce pain, improve quality of life, and lower pharmacotherapy use. METHODS: Sixty-five subjects with chronic low back pain were randomly assigned to SAM (N= 33) or placebo (N= 32) groups. Subjects self-applied SAM device bilaterality on the lower lumbar region for 4 hours daily for 8 weeks and completed daily pain diaries before, during, and after treatment. Subjects recorded pain reduction using a numeric rating scale (NRS), medication use, and physical activity using the Global Rating of Change (GROC) and Oswestry Disability Index (ODI). RESULTS: SAM treatment significantly reduced chronic lower back pain from baseline relative to placebo treatment (p< 0.0001). SAM treated subjects reported significantly lower back pain at 4 weeks, with the highest pain reduction (-2.58 points NRS, p< 0.0001) reported at 8 weeks. Similar trends were observed in improved physical activity (3.48 GROC, p< 0.0001, 69–88% ODI, p< 0.0001) and 22.5% (15.2 morphine milligram equivalent) reduction in the use of opioid medication from baseline to 8 weeks. CONCLUSION: Daily, home-use SAM treatment significantly improves the clinical symptoms of chronic lower back pain, improves physical mobility, and reduces daily medication use. SAM treatment is well-tolerated by patients and may be considered a safe, non-invasive treatment option for chronic discogenic, lower back pain.

show abstract

Low-intensity pulsed ultrasound: Nonunions

Cited by 26 publications

References 46 publications

The efficacy of low-level 940 nm laser therapy with different energy intensities on bone healing

The efficacy of low-level 940 nm laser therapy with different energy intensities on bone healing

A Low-Intensity Pulsed Ultrasound Interface ASIC for Wearable Medical Therapeutic Device Applications

Sustained acoustic medicine treatment of discogenic chronic low back pain: A randomized, multisite, double-blind, placebo-controlled trial

Contact Info

Product

Resources

About